431 related articles for article (PubMed ID: 11406167)
1. Mechanisms of resistance to cisplatin.
Kartalou M; Essigmann JM
Mutat Res; 2001 Jul; 478(1-2):23-43. PubMed ID: 11406167
[TBL] [Abstract][Full Text] [Related]
2. Recognition of cisplatin adducts by cellular proteins.
Kartalou M; Essigmann JM
Mutat Res; 2001 Jul; 478(1-2):1-21. PubMed ID: 11406166
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin resistance and oncogenes--a review.
Dempke W; Voigt W; Grothey A; Hill BT; Schmoll HJ
Anticancer Drugs; 2000 Apr; 11(4):225-36. PubMed ID: 10898536
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin.
Trimmer EE; Essigmann JM
Essays Biochem; 1999; 34():191-211. PubMed ID: 10730196
[TBL] [Abstract][Full Text] [Related]
5. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance.
Lanzi C; Perego P; Supino R; Romanelli S; Pensa T; Carenini N; Viano I; Colangelo D; Leone R; Apostoli P; Cassinelli G; Gambetta RA; Zunino F
Biochem Pharmacol; 1998 Apr; 55(8):1247-54. PubMed ID: 9719480
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin.
Reed E
Cancer Chemother Biol Response Modif; 1999; 18():144-51. PubMed ID: 10800481
[No Abstract] [Full Text] [Related]
7. Screening for modulators of cisplatin sensitivity: unbiased screens reveal common themes.
Nijwening JH; Kuiken HJ; Beijersbergen RL
Cell Cycle; 2011 Feb; 10(3):380-6. PubMed ID: 21239890
[TBL] [Abstract][Full Text] [Related]
8. The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast.
McA'Nulty MM; Lippard SJ
Mutat Res; 1996 Jan; 362(1):75-86. PubMed ID: 8538651
[TBL] [Abstract][Full Text] [Related]
9. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
[TBL] [Abstract][Full Text] [Related]
10. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines.
Yang Z; Faustino PJ; Andrews PA; Monastra R; Rasmussen AA; Ellison CD; Cullen KJ
Cancer Chemother Pharmacol; 2000; 46(4):255-62. PubMed ID: 11052622
[TBL] [Abstract][Full Text] [Related]
11. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
12. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
13. Loss of amine from platinum(II) complexes: implications for cisplatin inactivation, storage, and resistance.
Lau JK; Deubel DV
Chemistry; 2005 Apr; 11(9):2849-55. PubMed ID: 15744707
[TBL] [Abstract][Full Text] [Related]
14. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
15. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
Wang Z; Xu Z; Zhu G
Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy.
Makovec T
Radiol Oncol; 2019 Mar; 53(2):148-158. PubMed ID: 30956230
[TBL] [Abstract][Full Text] [Related]
17. Preclinical perspectives on platinum resistance.
Kelland LR
Drugs; 2000; 59 Suppl 4():1-8; discussion 37-8. PubMed ID: 10864225
[TBL] [Abstract][Full Text] [Related]
18. [Advance in studies on molecular mechanisms of cisplatin resistance and intervention with traditional Chinese medicines].
Liu L; Bian K
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(17):3216-20. PubMed ID: 25522600
[TBL] [Abstract][Full Text] [Related]
19. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin resistance in cell models: evaluation of metallomic and biological predictive biomarkers to address early therapy failure.
Espina M; Corte-Rodríguez M; Aguado L; Montes-Bayón M; Sierra MI; Martínez-Camblor P; Blanco-González E; Sierra LM
Metallomics; 2017 May; 9(5):564-574. PubMed ID: 28425536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
